samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > data protection - can anonymising data protect you?
PUBLICATIONS
European Biopharmaceutical Review

Data Protection - Can Anonymising Data Protect You?

The compilation, dissemination and use of databases containing human genetic information raise obvious data protection and privacy concerns. European Union Directive 95/46, implemented in the UK as the Data Protection Act 1998, sets out a rigorous regime of controls and rights concerning the processing of information about individuals. Those involved in the burgeoning bioinformatics sphere need to give careful thought to whether the legislation applies to their activities. This article will show that this may not always be entirely straightforward.The EU Directive and UK Act are concerned with the 'processing' of 'personal data'relating to living individuals. The definition of 'processing' in the legislation is all encompassing, including (but not being limited to) obtaining, organising, recording, holding, disclosing, using and even erasing the information. Therefore the application of the legislation depends more on what is meant by the term 'personal data'. Any information stored or manipulated using a computer qualifies as 'data', but to be 'personal' data the information must relate to a living individual.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Myles Jelf, Associate, Bristows Myles Jelf specialises in intellectual property law, with an emphasis on litigation. He has twice been seconded to clients' in-house legal teams, gaining experience that, together with his early training as an engineer, gives him a valuable insight into Bristows' clients' commercial needs.
Myles has worked for clients in a wide variety of industrial sectors, ranging from the production of shampoos to silicon chip fabrication. He also has experience concerning the application of EU competition law to intellectual property rights, and has represented clients' interests before the Competition Directorate of the European Commission. Within his IT law practice, Myles focuses on the regulation of data processing and personal data privacy, especially as it applies to Internet/ e-Business ventures.

spacer
Myles Jelf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Eurofins enhances clinical and COVID-19 testing offering in Japan through acquisition of Genetic Lab Co.,Ltd.

Eurofins Scientific (EUFI.PA), the global scientific leader in bioanalytical testing and a leader in clinical diagnostics testing, announces a share purchase agreement with Transgenic Inc. (2342:JP, Tokyo stock exchange) to acquire Genetic Lab Co.,Ltd. (“G Lab”), a molecular biology based testing provider for diagnostics, biomarker development and drug discovery.
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement